Preterm birth is the most common cause of neonatal morbidity and mortality globally, aff ecting about 15 million children every year. 1 Of children born preterm, an estimated 2·4 million (15·6%) are born extremely preterm (before 28 weeks gestation) or very preterm (before 32 weeks gestation). 1 Furthermore, some 1 million children every year die as a consequence of preterm birth or its complications. 1 In 2014, the Preterm Birth Priority Setting Partnership in the UK identifi ed prediction and prevention of preterm birth as the top research priority in this area. 2 Progesterone has been considered a promising therapeutic agent to prevent preterm birth. Having been assessed in several small, randomised trials in the 1960s and 1970s, a meta-analysis by Keirse 3 identifi ed a reduction in the occurrence of preterm birth after antenatal use of progesterone. This fi nding inspired others to undertake new randomised trials, and in 2003, both Meis and colleagues 4 and Da Fonseca and colleagues 5 reported a reduction of preterm birth in women with previous preterm birth after treatment with 17α-hydroxyprogesterone caproate and vaginal progesterone, respectively. Subsequent meta-analysis (incorporating both intramuscular and vaginal preparations) confi rmed that progestogens could prolong pregnancy, and were associated with a reduction in shortterm neonatal mortality and morbidity. 6 However, it remains uncertain whether this approach is associated with improvements in long-term outcomes for children. Whereas longer duration of pregnancy is often related to Progestogens and preterm birth-not the hoped for panacea? long as most of us remember. Its effi cacy has never been properly established or quantifi ed in chronic diseases, and is probably not as great as many would believe. Its safety is also questioned, 9 not just in overdose. 10 Is recommending it as the universal fi rst-line analgesic in osteoarthritis still tenable?
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better neonatal outcomes, a longer stay in a hazardous uterine environment might be harmful. 7 In The Lancet, Jane Norman and colleagues 8 report the eff ect of vaginal progesterone (200 mg daily taken from 22-24 to 34 weeks of gestation) in 1228 women at increased risk for preterm birth on early child development at 2 years of age. They did a randomised, multicentre, placebo-controlled study using rigorous standards, including an assessment of maternal compliance with medication, an unbiased assessment of outcomes, and used a sample size larger than all of the previously published studies combined. The authors report three primary family-centred outcomes, an obstetric outcome (fetal death or delivery before 34 weeks and 0 days of gestation), a neonatal outcome (composite of death, bronchopulmonary dysplasia, and brain injury), and a childhood outcome (Bayley-III cognitive composite score), refl ecting the fact that the eff ect of the intervention is through the prolongation of pregnancy, with an anticipated benefi t in improved neonatal and child health. Progesterone had no signifi cant eff ect on the primary obstetric outcome (odds ratio adjusted for multiple comparisons [OR] 0·86, 95% CI 0·61-1·22) or neonatal outcome (OR 0·62, 0·38-1·03).
Although the OPPTIMUM study itself shows no diff erence on the primary obstetric and neonatal outcome, all obstetric and neonatal outcomes showed a reduction in the occurrence of unwanted neonatal outcomes after the administration of progesterone (neonatal death, unadjusted OR 0·17, 95% CI 0·06-0·49; brain injury on ultrasound 0·50, 0·31-0·84). However, there was no identifi able improvement in child development when assessed at 2 years of age (cognitive score, progesterone group vs placebo group, 97·3 [SD 17·9] vs 97·7 [17·5]; diff erence in means -0·48, 95% CI -2·77 to 1·81). It will be important to incorporate these fi ndings into subsequent updates of the Cochrane Systematic Reviews on this topic.
First, the results from OPPTIMUM highlight the importance of perinatal trials to routinely follow up maternal and child participants after birth. As shown by Norman and colleagues, the risk-benefi t ratio of any perinatal intervention might vary considerably according to eff ects on the woman and her infant, both immediately after birth and extending into childhood, as has been shown with the use of antibiotics for women in spontaneous preterm labour, or the eff ects of multiple doses of corticosteroids.
9,10 It could be assumed that when an intervention does not infl uence the mechanism it aims to improve-for example prolongation of pregnancy-it does not work. However, the opposite is not guaranteed: successful short-term improvements in health do not necessarily correlate with improvements in longer-term health outcomes. Although this might be a message that complicates the lives not only of researchers, but also of research funders, it is an important reality. Researchers should consider the long-term eff ects for both neonates and their families; every study of a perinatal intervention that shows short-term benefi ts should ideally include longer-term follow-up of participants to assess potential benefi ts and harms.
Second, careful consideration of the interpretation of the 2-year outcome is needed. It is interesting that the better neonatal outcome of vaginal progesterone does not translate to any benefi t in terms of longerterm child health. Although there might be associations between short-term morbidity and longer-term health, the lack of observed eff ect could refl ect both the impact of a multitude of postnatal factors (eg, socioeconomic factors, attention to the child) on child development, as well as the relative imprecision of the Bayley-III cognitive scale, meaning that more subtle developmental variations might go undetected. 11 Third, since OPPTIMUM also indicates that at 2 years of age no harm is to be anticipated from progesterone, the decision to use progesterone or not also becomes an issue of shared decision making. The most important short-term perinatal outcome for preterm birth, neonatal death, occurred in one of the children in the progesterone group compared with six in the placebo group (unadjusted OR 0·17, 95% CI 0·06-0·49). Similarly, a meta-analysis had already indicated that progesterone reduced the risk of perinatal mortality in women with a history of spontaneous preterm birth (risk ratio [RR] 0·50, 95% CI 0·33-0·75) and in women with an ultrasoundidentified short cervix (RR 0·74, 95% CI 0·42-1·29). 6 Obviously, for parents who have suff ered the loss of a child due to prematurity the decision to use progesterone in a subsequent pregnancy might be infl uenced by this information. This decision should be weighed against the fact that in Norman and colleagues' study 8 the diff erence in neonatal death rate was not seen in the death rate at the age of 2 years (hazard ratio 1·28, 95% CI 0·66-2·51). www.thelancet.com Vol 387 May 21, 2016
With 15 million premature babies born worldwide every year, premature birth is the biggest problem in obstetrics. 1 It is not only the most common reason that newborn babies die, 1 but is also an important cause of long-term brain, bowel, lung, and eye damage. Antenatal steroids reduce the risk of lung disease, intracranial bleeding, and death 2 and magnesium sulphate reduces cerebral palsy. 3 Obstetricians often also prescribe uterine relaxant, or tocolytic, drugs to delay birth, albeit without much evidence to support this practice. Current policy 4,5 is generally to limit tocolysis to 48 h to gain the maximum benefi t from steroids and allow in-utero transfer to a suitable intensive-care facility. But which tocolytic should be used?
Five drug groups have been tried. β adrenoceptor agonists and cyclooxygenase inhibitors have been all but abandoned due to side-eff ects and magnesium sulphate, although neuroprotective, is an ineff ective tocolytic. 6 Only calcium-channel blockers, of which nifedipine is the most widely studied, and the oxytocin antagonist atosiban remain in widespread use. Three direct comparison trials have been done but were small [7] [8] [9] and two were unregistered. 7, 8 Eff orts to compare the two drugs by indirect 10 or network meta-analyses 11 have been unconvincing because of the variable methodological quality of the component trials. Nevertheless, most international guidelines (apart from those in the USA where atosiban is unavailable) currently recommend one of these drugs as fi rst-line tocolytic drugs. 4, 5 In The Lancet, Elvira van Vliet and colleagues 12 present fi ndings from APOSTEL III, a large, multicentre, randomised trial to compare perinatal outcomes after 48 h of tocolysis with nifedipine versus atosiban in 510 women with threatened preterm birth (25-34 weeks of gestation). 254 women were randomly assigned to oral nifedipine and 256 women to intravenous atosiban, with
Tocolysis and preterm labour
Future use of standardised outcomes can prevent the variety of outcomes that have been used in the studies done thus far, 12 and individual patient data meta-analysis of progestogens to prevent preterm birth will allow a better assessment of treatment benefi ts, particularly for subgroups of women. The OPPTIMUM study is a step forward in the understanding of progesterone as a treatment in women at risk for preterm birth. The study also highlights the importance for perinatal trialists to incorporate at the outset an undertaking to continue to assess longer-term outcomes, to use standardised outcomes, and to integrate the obtained results. This can best be achieved in a global collaboration of those working on this topic. 
